{"url_path":"/sec/slno/8-k/2026-05-18/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","accession_number":"0001193125-26-228016","cik":"0001484565","ticker":"SLNO","issuer_name":"SOLENO THERAPEUTICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1484565/0001193125-26-228016-index.html","primary_entity_key":"0001484565","primary_entity_name":"SOLENO THERAPEUTICS INC"},"word_count":148,"has_tables":true,"body_markdown":"Item 3.01.\n\nNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing\n\nOn May 18, 2026, the Company notified The Nasdaq Capital Market (“Nasdaq”) of the consummation of the Merger and requested that Nasdaq (i) suspend trading of and delist the Shares and (ii) file with the SEC a notification of removal from listing and/or registration on Form 25 to effect the delisting of all Shares from Nasdaq and the deregistration of such Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In addition, the Company intends to file a certification and notice of termination of registration on Form 15 with the SEC requesting the termination of registration of the Shares under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act."}